score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3596	178.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat77	MEL-IPI_Pat77-Tumor-SM-4DK33	MEL-IPI_Pat77-Normal-SM-53U63
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.L177M	0.2603	242.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106						0				MAP2K1 p.L177M (Missense)	0.0	MEL-IPI_Pat77	MEL-IPI_Pat77-Tumor-SM-4DK33	MEL-IPI_Pat77-Normal-SM-53U63
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat77		
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Nonsense	p.Q347*	0.2994	167.0	0.0	0.0																Investigate Actionability	0.0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				PTPN11 p.Q347* (Nonsense)		MEL-IPI_Pat77	MEL-IPI_Pat77-Tumor-SM-4DK33	MEL-IPI_Pat77-Normal-SM-53U63
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.RVAEL7fs	0.381	21.0	0.0	0.0																					0				CDKN2A p.RVAEL7fs (Frameshift)		MEL-IPI_Pat77	MEL-IPI_Pat77-Tumor-SM-4DK33	MEL-IPI_Pat77-Normal-SM-53U63
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.S569F	0.2537	205.0	0.0	0.0																					0				FGFR2 p.S569F (Missense)		MEL-IPI_Pat77	MEL-IPI_Pat77-Tumor-SM-4DK33	MEL-IPI_Pat77-Normal-SM-53U63
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.RVAEL7fs	0.3333	24.0	0.0	0.0																					0				CDKN2A p.RVAEL7fs (Frameshift)		MEL-IPI_Pat77	MEL-IPI_Pat77-Tumor-SM-4DK33	MEL-IPI_Pat77-Normal-SM-53U63
Biologically Relevant				Copy Number	COL1A1	Amplification				0.0	0.0																					0				COL1A1 Amplification		MEL-IPI_Pat77	MEL-IPI_Pat77-Tumor-SM-4DK33	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat77		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.844																									0				COSMIC Signature (version 2) 7 (84%)		MEL-IPI_Pat77		
